following a full submission assessed under the ultra-orphan process
pasireotide (as pamoate) (Signifor®) is accepted for use within NHS Scotland.
Indication under review: Treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
Pasireotide administered every four weeks was significantly superior to an active control group (comprising other somatostatin analogues administered monthly) for the primary endpoint of biochemical control, in patients with inadequately controlled acromegaly following treatment with a somatostatin analogue for at least six months.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice220KB (PDF)
Medicine details
- Medicine name:
- pasireotide (as pamoate) (Signifor)
- SMC ID:
- 1048/15
- Indication:
- Treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 September 2015